Chapter

Detecting Minimal Residual Disease and Recurrence

Concepts

MRD Detection
"An emerging application of liquid biopsy that holds significant promise for improving cancer care is its ability to detect minimal residual disease (MRD) and recurrence after treatment. Recent resear
Kidney Monitoring
"Similarly, in metastatic kidney cancer, researchers showed that tracking ctDNA over time can offer important insights for patients receiving standard immunotherapy or targeted drugs. They found that
Recurrence Monitoring
"In another study in melanoma, ctDNA detected after surgery identified patients at highest risk of recurrence, and its continued presence during follow-up treatment signaled early relapse and poor sur
Clinical Barriers
"Although liquid biopsy has shown promise in enhancing current methods of cancer detection and monitoring, challenges remain that limit its routine clinical use (see Sidebar 55). Researchers have high